An overview of lung cancer

Respiratory Care Clinics of North America

Volumn 9, Issue 1, 2003, Pages 1-25

  Sachs, Sharona ^a,b   Fiore, John J ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; BCG VACCINE; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; METHOTREXATE; NAVELBINE; PACLITAXEL; TOPOTECAN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CIGARETTE SMOKING; COMORBIDITY; ENVIRONMENTAL FACTOR; HEALTH PROGRAM; HUMAN; KIDNEY FAILURE; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MINIMAL RESIDUAL DISEASE; NAUSEA; OCCUPATIONAL EXPOSURE; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; TUBERCULOSIS; VOMITING;

EID: 0038204573     PISSN: 10785337     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5337(02)00081-3     Document Type: Review

References (64)

1. Feinstein MB, Bach PB. Epidemiology of lung cancer. Chest Surg Clin N Am 2000; 10(4):653-61.
2. Smith RA, Glynn TJ. Epidemiology of lung cancer. Radiol Clin N Am 2000;38(3):453-70.
3. Bach PB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early stage lung cancer. N Engl J Med 1999;341:1198-205.
4. Christiani DC. Smoking and the molecular epidemiology of lung cancer. Clin Chest Med 2000;21(1):87-93.
5. Risch HA, Howe GR, Jain M, et al. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 1993;138:281-93.
6. Petty TL. Simple office spirometry. Clin Chest Med 2001;22:845-59.
7. Skilrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease: a prospective, matched, controlled study. Ann Intern Med 1986;105: 503-7.
8. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997;315:980-8.
9. Hammond EC, Selikoff IJ, Seidman H. Asbestos exposure, cigarette smoking, and death rates. Ann N Y Acad Sci 1979;330:473-90.
10. Turner-Warwick M, Lebowitz M, Burrows B, et al. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980;35:496-9.
11. Hinds MW, Cohen HI, Kolonel LN. Tuberculosis and lung cancer risk in nonsmoking women. Am Rev Respir Dis 1982;125:776-8.
12. Ad Hoc Committee of the Assembly on Clinical Problems. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med 1997;156:320-32.
13. Carr DT, Holoye PY, Hong WK. Bronchogenic carcinoma. In: Murray JF, Nadel JA, editors. Textbook of respiratory medicine, vol. 2. 2nd edition. Philadelphia: WB Saunders; 1994: p. 1541.
14. Daly BDT, Mueller JD, Faling LJ, et al. N2 lung cancer: outcome in patients with false-negative computed tomographic scans of the chest. J Thorac Cardiovasc Surg 1993; 105:904-11.
15. Goldstraw P. Surgical oncologic principles. Chest Surg Clin N Am 2001;11(1):1-15.
16. Harpole DH, Herndon JE, Young WG, et al. Stage I nonsmall cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995;76:787-96.
17. Kayser K, Bulzebruck H, Probst G, et al. Retrospective and prospective tumor staging evaluating prognostic factors in operated bronchus carcinoma patients. Cancer 1987;59: 355-61.
18. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111:1710-7.
19. Mountain CF. New prognostic factors in lung cancer: biologic prophets of cancer cell aggression. Chest 1995;108:246-54.
20. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-23.
21. Mountain CF, Lukeman JM, Hammar SP, et al. Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol 1997;35:147-56.
22. Patz EF, Rossi S, Harpole DH, et al. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest 2000;117:1568-71.
23. Walsh GL, Pisters KMW, Stevens C. Treatment of stage I lung cancer. Chest Surg Clin N Am 2001;11(1):17-37.
24. Adachi M, Taki T, Cheng-long H, et al. Reduced integrin α3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung. J Clin Oncol 1998;16:1060-7.
25. Apolinario RM, van der Valk P, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small cell lung cancer. J Clin Oncol 1997;15:2456-66.
26. Betticher DC, Heighway J, Hasleton PS, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 1996; 73:294-300.
27. Dalquen P, Moch H, Feichter G, et al. DNA aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma. Virchows Arch 1997;431:173-9.
28. Decaussin M. Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999; 189:369-77.
29. Fontanini G, Boldrini L, Chine S, et al. Expression of vascular endothelial growth factor mRNA in non-small-cell carcinomas. Br J Cancer 1999;79:363-9.
30. Fontanini G, Vignati S, Chine S, et al. 67-kilodalton laminin receptor expression correlates with worse prognostic indicators in non-small cell lung carcinomas. Clin Cancer Res 1997;3:227-31.
31. ink-4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 1999;5:791-800.
32. Hirata T, Fukuse T, Naiki H, et al. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 1998;58:1108-10.
33. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993;53:1-4.
34. Ikonen JT, Ojala A, Salenius J-P, et al. DNA flow cytometry in surgically treated lung cancer: prognostic significance. Scand Cardiovasc J 1999;33:228-33.
35. Merkel DE, Dressler LG, McGuire WL. Flow cytometry, cellular DNA content, and prognosis in human malignancy. J Clin Oncol 1987;5:1690-703.
36. Nishio M, Koshikowa T, Kuroishi T, et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancers. J Clin Oncol 1996;14: 497-502.
37. Pastorini U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997;15:2858-65.
38. Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 1999;160:1269-73.
39. Strauss GM. Prognostic markers in resectable non-small cell lung cancer. Hematol Oncol Clin N Am 1997;11(3):409-34.
40. Strauss GM, Kwiatkowski DJ, Harpole DH, et al. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 1995;13:1265-79.
41. Lubin JH, Blot WJ. Assessment of lung cancer risk factors by histologic categories. J Natl Cancer Inst 1984;73(2):383-9.
42. Ernster VL. Female lung cancer. Annu Rev Public Health 1996; 17:97-114.
43. Yesner R, Aisner SC, Campobosso O, et al. Classification of lung cancer histology. N Engl J Med 1985;312(10):652-3.
44. Murren J, Glatstein E, Pass HI. Small cell lung cancer. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th edition. Philadelphia: Lippincott, Williams and Wilkins; 2001. p. 990-1006.
45. von Pawel J, Schiller J, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol 1999;17(2):658-67.
46. von Pawel J, Gatzemeier U, Pujol J, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small cell lung cancer. J Clin Oncol 2001;19(6):1743-9.
47. Schiller J, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19(8):2114-22.
48. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346(2): 85-91.
49. Bunn PA, Kelly K, Crowley J, et al. Preliminary toxicity results from Southwest Oncology Group Trial (SWOG) 9705: a phase II trial of cisplatin, etoposide and paclitaxel (PET) with G-CSF in untreated patients with extensive small cell lung cancer. Proc Am Soc Clin Oncol 1999;18:468a.
50. Jacobs SA, Jett JR, Belani CP, et al. Topotecan and paclitaxel, an active couplet, in untreated extensive small cell lung cancer. Proc Am Soc Clin Oncol 1999;18:470a.
51. Shepherd FA, Evans WK, Feld R, et al. Adjuvant chemotherapy following surgical resection for small cell carcinoma of the lung. J Clin Oncol 1988;6(5):832-8.
52. Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994;106(6):S320-3.
53. Pignon J, Arriagada R, Ihde D, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327(23):1618-24.
54. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10(6):890-5.
55. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993; 11(2):336-44.
56. Goto K, Nishiwaki Y, Takada M, et al. Final results of a phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage SCLC: the Japan Clinical Oncology (JCOG) study. Proc Am Soc Clin Oncol 1999;18:468a.
57. Jeremic B, Shibamato Y, Acimovic L, et al. Initial versus delayed accelerated hyper-fractionated radiation therapy and concurrent chemotherapy in limited SCLC: a randomized study. J Clin Oncol 1997;15(3):893-900.
58. Perry MC, Herndon JE, Baton WL, et al. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B study 8083. J Clin Oncol 1998;16(7):2466-7.
59. Work E, Nielsen O, Bentzen S, et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. J Clin Oncol 1997;15(9):3030-7.
60. Turrisi AT, Kyungmann K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340(4):265-71.
61. Aupérin A, Arriagada R, Pignon J, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999;341(7):476-84.
62. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. Eur J Cancer 1997;33(11):1752-8.
63. Meyers CA, Byrne KS, Komaki R, et al. Cognitive defects in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 1995;12(3):231-5.
64. Grant SC, Kris MG, Houghton AN, et al. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus bacillus Calmette-Guérin. Clin Cancer Res 1999;5(6):1319-23.